Geron Corp

XNASHealth care

Last traded price · USD

$1.08

+0.00%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:51 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $1.08
Volume: 1,003
Day's high: —
Day's low: —

In brief

Geron Corp is a health care company listed on Nasdaq, valued at about $694M.
Its shares closed at $1.08 on 4 Nov 2026, down 6.1% over the past year.
From India you can buy GERN in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Geron Corp (GERN) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole GERN share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade GERN options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: −10.7% (SPY −1.6%, XLV +13.5%). 3 months: −33.7% (SPY −0.4%, XLV +15.5%). 1 year: −6.1% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: GERN, SPY and XLV · as of 4 Nov 2026
Rose 16.1% on 4 Nov 2026
The 4 Nov 2026 gain of 16.1% was 5.4× its average daily move of 3.0% over the past year, and its largest one-day gain since 5 Aug 2026.
Daily closes, split-adjusted · as of 4 Nov 2026
9.9 days to cover short interest
74.6M shares were sold short at the 15 Oct 2026 settlement, 11.6% of the 642.5M shares outstanding; covering them would take 9.9 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $1.08 was 14.2% below its 50-day average ($1.26) and 24.0% below its 200-day average ($1.42). It has closed below the 200-day for 41 sessions, since 9 Sep 2026. The 50-day average crossed below the 200-day on 24 Sep 2026, 29 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
19% of the way up its 52-week range
Closed at $1.08 on 4 Nov 2026: 46.3% below the 52-week high of $2.01 (19 Feb 2026) and 25.5% above the low of $0.86 (30 Oct 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−10.7%

6 months−31.6%

1 year−6.1%

5 years−34.9%

Newswire

About

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Website

Notable moves

February 26, 2025
−32.07%
March 15, 2024
+92.00%
January 4, 2023
+32.92%

Newswire

About

Website

Notable moves

February 26, 2025
−32.07%
March 15, 2024
+92.00%
January 4, 2023
+32.92%

Geron Corp

XNASHealth care

Last traded price · USD

$1.08

+0.00%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:51 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $1.08
Volume: 1,003
Day's high: —
Day's low: —

In brief

Geron Corp is a health care company listed on Nasdaq, valued at about $694M.
Its shares closed at $1.08 on 4 Nov 2026, down 6.1% over the past year.
From India you can buy GERN in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Geron Corp (GERN) shares from India?

Do I need the price of a whole GERN share to invest?

How much can I invest in US stocks in a year?

Can I trade GERN options or futures?

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: −10.7% (SPY −1.6%, XLV +13.5%). 3 months: −33.7% (SPY −0.4%, XLV +15.5%). 1 year: −6.1% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: GERN, SPY and XLV · as of 4 Nov 2026
Rose 16.1% on 4 Nov 2026
The 4 Nov 2026 gain of 16.1% was 5.4× its average daily move of 3.0% over the past year, and its largest one-day gain since 5 Aug 2026.
Daily closes, split-adjusted · as of 4 Nov 2026
9.9 days to cover short interest
74.6M shares were sold short at the 15 Oct 2026 settlement, 11.6% of the 642.5M shares outstanding; covering them would take 9.9 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $1.08 was 14.2% below its 50-day average ($1.26) and 24.0% below its 200-day average ($1.42). It has closed below the 200-day for 41 sessions, since 9 Sep 2026. The 50-day average crossed below the 200-day on 24 Sep 2026, 29 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
19% of the way up its 52-week range
Closed at $1.08 on 4 Nov 2026: 46.3% below the 52-week high of $2.01 (19 Feb 2026) and 25.5% above the low of $0.86 (30 Oct 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−10.7%

6 months−31.6%

1 year−6.1%

5 years−34.9%

Newswire

About

Website

Notable moves

February 26, 2025
−32.07%
March 15, 2024
+92.00%
January 4, 2023
+32.92%

Newswire

About

Website

Notable moves

February 26, 2025
−32.07%
March 15, 2024
+92.00%
January 4, 2023
+32.92%

Geron Corp

Geron Corp in brief

Behind SPY and its sector fund XLV over 1 year

Rose 16.1% on 4 Nov 2026

9.9 days to cover short interest

Below its 50- and 200-day averages

19% of the way up its 52-week range

Geron Corp

Geron Corp in brief

Behind SPY and its sector fund XLV over 1 year

Rose 16.1% on 4 Nov 2026

9.9 days to cover short interest

Below its 50- and 200-day averages

19% of the way up its 52-week range